{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:06:05Z","timestamp":1782889565208,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s12350-021-02731-6","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T21:02:33Z","timestamp":1628802153000},"page":"24-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Quantitative myocardial perfusion response to adenosine and regadenoson in patients with suspected coronary artery disease"],"prefix":"10.1016","volume":"29","author":[{"given":"Tanja","family":"Kero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Saraste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Lagerqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"S\u00f6rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essi","family":"Pikkarainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lubberink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhani","family":"Knuuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s12350-021-02731-6_bib1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0735-1097(94)90424-3","article-title":"Safety profile of adenosine stress perfusion imaging: Results from the Adenoscan Multicenter Trial Registry","volume":"23","author":"Cerqueira","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-021-02731-6_bib2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2967\/jnmt.109.065581","article-title":"Advances in pharmacologic stress agents: Focus on regadenoson","volume":"38","author":"Johnson","year":"2010","journal-title":"J Nucl Med Technol"},{"key":"10.1007\/s12350-021-02731-6_bib3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.nuclcard.2007.06.114","article-title":"Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial","volume":"14","author":"Iskandrian","year":"2007","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02731-6_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jcmg.2008.02.003","article-title":"Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results","volume":"1","author":"Cerqueira","year":"2008","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02731-6_bib5","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.jacc.2005.05.097","article-title":"Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging","volume":"46","author":"Hendel","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-021-02731-6_bib6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.amjcard.2012.05.038","article-title":"Comparison and effectiveness of regadenoson versus dipyridamole on stress electrocardiographic changes during positron emission tomography evaluation of patients with hypertrophic cardiomyopathy","volume":"110","author":"Bravo","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1007\/s12350-021-02731-6_bib7","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1007\/s00259-011-1853-6","article-title":"Comparison of the myocardial blood flow response to regadenoson and dipyridamole: A quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET","volume":"38","author":"Goudarzi","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1007\/s12350-021-02731-6_bib8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jcmg.2014.11.016","article-title":"Regadenoson versus dipyridamole hyperemia for cardiac PET imaging","volume":"8","author":"Johnson","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02731-6_bib9","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/s12350-011-9491-8","article-title":"Properties of an ideal PET perfusion tracer: New PET tracer cases and data","volume":"19","author":"Maddahi","year":"2012","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02731-6_bib10","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.CIR.70.4.724","article-title":"Quantification of regional myocardial blood flow in vivo with H215O","volume":"70","author":"Bergmann","year":"1984","journal-title":"Circulation"},{"key":"10.1007\/s12350-021-02731-6_bib11","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/01.CIR.87.2.512","article-title":"Direct comparison of [13N]ammonia and [15O]water estimates of perfusion with quantification of regional myocardial blood flow by microspheres","volume":"87","author":"Bol","year":"1993","journal-title":"Circulation"},{"key":"10.1007\/s12350-021-02731-6_bib12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s12350-010-9256-9","article-title":"Quantification of myocardial blood flow and flow reserve: Technical aspects","volume":"17","author":"Klein","year":"2010","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02731-6_bib13","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.jacc.2014.05.069","article-title":"Quantitative assessment of myocardial perfusion in the detection of significant coronary artery disease: Cutoff values and diagnostic accuracy of quantitative [(15)O]H2O PET imaging","volume":"64","author":"Danad","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-021-02731-6_bib14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.nuclcard.2007.02.016","article-title":"Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans","volume":"14","author":"Lieu","year":"2007","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02731-6_bib15","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.jcmg.2009.06.013","article-title":"Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics","volume":"2","author":"Mekkaoui","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02731-6_bib16","doi-asserted-by":"crossref","unstructured":"Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-42.","DOI":"10.1161\/hc0402.102975"},{"key":"10.1007\/s12350-021-02731-6_bib17","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00259-011-1730-3","article-title":"Automatic generation of absolute myocardial blood flow images using [15O]H2O and a clinical PET\/CT scanner","volume":"38","author":"Harms","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1007\/s12350-021-02731-6_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0962280214537344","article-title":"Quantitative imaging biomarkers: A review of statistical methods for technical performance assessment","volume":"24","author":"Raunig","year":"2015","journal-title":"Stat Methods Med Res"},{"key":"10.1007\/s12350-021-02731-6_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s12350-012-9636-4","article-title":"Regadenoson pharmacologic rubidium-82 PET: A comparison of quantitative perfusion and function to dipyridamole","volume":"20","author":"Cullom","year":"2012","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02731-6_bib20","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s10554-011-9949-4","article-title":"The effect of obesity on regadenoson-induced myocardial hyperemia: A quantitative magnetic resonance imaging study","volume":"28","author":"DiBella","year":"2012","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02731-6_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1532-429X-15-85","article-title":"Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance","volume":"15","author":"Vasu","year":"2013","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1007\/s12350-021-02731-6_bib22","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.4244\/EIJV8I10A180","article-title":"Comparison of intravenous adenosine and intravenous regadenoson for the measurement of pressure-derived coronary fractional flow reserve","volume":"8","author":"Arumugham","year":"2013","journal-title":"EuroIntervention"},{"key":"10.1007\/s12350-021-02731-6_bib23","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jcin.2011.07.011","article-title":"Clinical utility of regadenoson for assessing fractional flow reserve","volume":"4","author":"Nair","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1007\/s12350-021-02731-6_bib24","first-page":"369","article-title":"Use of regadenoson for measurement of fractional flow reserve","volume":"83","author":"Prasad","year":"2014","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1007\/s12350-021-02731-6_bib25","doi-asserted-by":"crossref","unstructured":"van Nunen LX, Lenders GD, Schampaert S, van \u2019t Veer M, Wijnbergen I, Brueren GR, et al. Single bolus intravenous regadenoson injection versus central venous infusion of adenosine for maximum coronary hyperaemia in fractional flow reserve measurement. EuroIntervention. 2015;11:905-13.","DOI":"10.4244\/EIJY14M08_10"},{"key":"10.1007\/s12350-021-02731-6_bib26","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jcmg.2009.04.011","article-title":"Regadenoson induces comparable left ventricular perfusion defects as adenosine: A quantitative analysis from the ADVANCE MPI 2 trial","volume":"2","author":"Mahmarian","year":"2009","journal-title":"JACC Cardiovas Imaging."},{"key":"10.1007\/s12350-021-02731-6_bib27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jacc.2007.10.014","article-title":"Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: A randomized, double-blind, placebo-controlled crossover trial","volume":"51","author":"Gaemperli","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-021-02731-6_bib28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/ehjci\/jez080","article-title":"Quantitative myocardial perfusion positron emission tomography and caffeine revisited with new insights on major adverse cardiovascular events and coronary flow capacity","volume":"20","author":"Kitkungvan","year":"2019","journal-title":"Eur Heart J Cardiovasc IMAGING"},{"key":"10.1007\/s12350-021-02731-6_bib29","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s12350-016-0761-3","article-title":"Noninvasive PET quantitative myocardial blood flow with regadenoson for assessing cardiac allograft vasculopathy in orthotopic heart transplantation patients","volume":"24","author":"Pampaloni","year":"2017","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-021-02731-6_bib30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2967\/jnmt.117.199463","article-title":"Cardiac displacement during (13)N-ammonia myocardial perfusion PET\/CT: Comparison between adenosine- and regadenoson-induced stress","volume":"46","author":"Vleeming","year":"2018","journal-title":"J Nucl Med Technol"},{"key":"10.1007\/s12350-021-02731-6_bib31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00005344-200301000-00017","article-title":"Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: Potential for use in myocardial perfusion imaging","volume":"41","author":"Trochu","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1007\/s12350-021-02731-6_bib32","first-page":"1848","article-title":"Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET","volume":"40","author":"Kaufmann","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1007\/s12350-021-02731-6_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40658-016-0171-2","article-title":"Quantitative myocardial blood flow imaging with integrated time-of-flight PET-MR","volume":"4","author":"Kero","year":"2017","journal-title":"EJNMMI Phys."},{"key":"10.1007\/s12350-021-02731-6_bib34","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.amjcard.2009.12.072","article-title":"Incidence of caffeine in serum of patients undergoing dipyridamole myocardial perfusion stress test by an intensive versus routine caffeine history screening","volume":"105","author":"Banko","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1007\/s12350-021-02731-6_bib35","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/nu10081083","article-title":"Effects of caffeine on myocardial blood flow: A systematic review","volume":"10","author":"van Dijk","year":"2018","journal-title":"Nutrients"},{"key":"10.1007\/s12350-021-02731-6_bib36","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10554-014-0419-7","article-title":"Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: A prospective, randomized, multicenter study","volume":"30","author":"Tejani","year":"2014","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02731-6_bib37","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s10554-017-1157-4","article-title":"Effects of caffeine intake prior to stress cardiac magnetic resonance perfusion imaging on regadenoson- versus adenosine-induced hyperemia as measured by T1 mapping","volume":"33","author":"van Dijk","year":"2017","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1007\/s12350-021-02731-6_bib38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/FJC.0b013e318046f364","article-title":"Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist","volume":"49","author":"Zhao","year":"2007","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-021-02731-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12350-021-02731-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123002350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123002350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-021-02731-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:09:03Z","timestamp":1761026943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358123002350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1071358123002350"],"URL":"https:\/\/doi.org\/10.1007\/s12350-021-02731-6","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative myocardial perfusion response to adenosine and regadenoson in patients with suspected coronary artery disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-021-02731-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 THE AUTHORS. Published by ELSEVIER INC. on behalf of American Society of Nuclear Cardiology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}